Phaseline

Companies › Amylyx Pharmaceuticals

Amylyx Pharmaceuticals: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 2 Phase 2, 1 Phase 3, 1 Phase 1; Metabolic and endocrine, Neurology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Avexitide
Glucagon-like peptide 1 receptor antagonist
GLP1RPhase 3Post Bariatric HypoglycemiaFeb 2027
AMX0035
Proprietary formulation of taurursodiol and sodium phenylbutyrate
–Phase 2Wolfram Syndrome; Type 1 Diabetes (T1D)May 2028
AMX0114
Antisense oligonucleotide targeting calpain-2 mRNA
CAPN2Phase 1ALSFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06747468AvexitidePhase 3Post Bariatric HypoglycemiaMetabolic and endocrineFeb 2027
NCT06665165AMX0114Phase 1ALSNeurologyFeb 2027
NCT05676034AMX0035Phase 2Wolfram SyndromeMetabolic and endocrineMay 2028
NCT07699380AMX0035Phase 2Type 1 Diabetes (T1D)Metabolic and endocrineDec 2029

From the company's SEC filings

Cash and short-term investments of $768m on 2026-09-30; operating cash outflow about $137m a year; runway about 67 months at that burn, to May 2032; 3 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 16 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

GLP1R (1) CAPN2 (1)

Companies with the same targets

Eli Lilly Novo Nordisk Roche Hangzhou Sciwind Biosciences Hangzhou Zhongmei Huadong Pharmaceutical Hanmi Pharmaceutical Company AstraZeneca Amgen Regeneron Pharmaceuticals Green Valley (Shanghai) Pharmaceuticals

Companies built like this

Kailera Viking Therapeutics Beijing QL Biopharmaceutical MBX Biosciences Rhythm Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.